

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The results of the Phase III IFM/DFCI 2009 trial comparing conventional-dose treatment with 8 cycles of lenalidomide/bortezomib/dexamethasone (RVd) to high-dose treatment with RVd and autologous stem cell transplantation (ASCT) in the initial management of multiple myeloma (MM) in patients aged 65 or younger demonstrated a statistically significant improvement in _____ for the patients who underwent ASCT.

 - Progression-free survival (PFS)
 - Overall survival
 - Both a and b
 - Neither a nor b
- The SWOG-S0777 trial evaluating RVd versus Rd (lenalidomide/dexamethasone alone) for patients with previously untreated MM without an intent for immediate ASCT demonstrated _____ with RVd.

 - A significant improvement in PFS
 - No significant benefit in PFS
- The results of the Phase III TOURMALINE-MM1 trial of Rd with or without ixazomib for patients with relapsed or refractory MM failed to demonstrate a statistically significant improvement in PFS with the addition of ixazomib.

 - True
 - False
- The Phase III ELOQUENT-2 study demonstrated that treatment with elotuzumab in combination with lenalidomide and dexamethasone resulted in a significant improvement in _____ in comparison to lenalidomide and dexamethasone alone among patients with relapsed/refractory MM.

 - PFS
 - Time to next treatment
 - Both a and b
 - Neither a nor b
- The results of the Phase III RESONATE-2 trial evaluating ibrutinib versus chlorambucil for patients aged 65 or older with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma without 17p deletion demonstrated that single-agent ibrutinib is superior to chlorambucil in terms of _____.

 - PFS
 - Overall survival
 - Both a and b
 - Neither a nor b
- The Phase III GADOLIN trial of bendamustine with or without obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma demonstrated a statistically significant improvement in PFS with the addition of obinutuzumab.

 - True
 - False
- The Phase III Alliance A041202 study of front-line therapy for patients aged 65 or older with chronic lymphocytic leukemia is evaluating _____ with or without rituximab versus the combination of bendamustine and rituximab.

 - Idelalisib
 - Ibrutinib
 - Neither a nor b

POST-TEST

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. Which of the following anti-PD-1 antibodies has demonstrated antitumor activity in patients with Hodgkin lymphoma?
- a. Nivolumab
 - b. Pembrolizumab
 - c. Both a and b
9. The Phase II SIRIUS trial demonstrated that _____, an anti-CD38 monoclonal antibody, has clinically meaningful single-agent activity in patients with MM who have received at least 3 prior lines of therapy or have disease that is refractory to both a proteasome inhibitor and an immunomodulatory agent.
- a. Daratumumab
 - b. Pembrolizumab
 - c. Elotuzumab
10. A recent study by Nowakowski and colleagues demonstrated that for patients with newly diagnosed diffuse large B-cell lymphoma, the negative effect of the non-GCB phenotype on outcomes is mitigated by the addition of _____ to R-CHOP.
- a. Nivolumab
 - b. Lenalidomide
 - c. Ifosfamide